Siponimod (Mayzent) vs Tascenso ODT

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

Siponimod (Mayzent)

Marketed by Novartis

Approved in Multiple Sclerosissmall molecule
Weak signal

NCT03623243 · Phase 3 · completed

The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.

Reported efficacy

Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) (Baseline, every 3 month up to the maximum of approximately 3 years): EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). (met)

Result source: NCT01665144

Tascenso ODT

Marketed by Cycle Pharmaceuticals Ltd. and partners

Approved in Multiple Sclerosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSiponimod (Mayzent)Tascenso ODT
Annualised relapse rate—Trial running · NCT04926818—Not reported
Free of 3-month confirmed disability progression (%)—Trial running · NCT04926818—Not reported
New or enlarging T2 lesions—Trial running · NCT04926818—Not reported

Annualised relapse rate

Siponimod (Mayzent)
—Trial running · NCT04926818
Tascenso ODT
—Not reported

Free of 3-month confirmed disability progression (%)

Siponimod (Mayzent)
—Trial running · NCT04926818
Tascenso ODT
—Not reported

New or enlarging T2 lesions

Siponimod (Mayzent)
—Trial running · NCT04926818
Tascenso ODT
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Tascenso ODT: no structured comparison results are available for Multiple Sclerosis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Siponimod (Mayzent)
EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). NCT01665144 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Siponimod (Mayzent): 4 of 4 rows · Tascenso ODT: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSiponimod (Mayzent)
Dropout rate
21.1%a
NCT03623243 · Phase 3
Discontinued due to AEs
8.1%a
NCT03623243 · Phase 3
Serious AEs
4.9%a
NCT03623243 · Phase 3
Most frequent reported AEs
a
headache 13.5%
urinary tract infection 8.6%
nausea 8.1%
NCT03623243 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Siponimod (Mayzent)'s landscape · Tascenso ODT's landscape